Novartis has completed its acquisition of US biopharma Chinook Therapeutics. The acquisition, which was announced in June, has a value of up to $3.5 billion.

Novartis has agreed to acquire US biopharma Chinook Therapeutics for $3.5 billion. Chinook has two late-stage drugs in development – Atrasentan and Zigakibart – to treat...